Advertisement

Archives of Pharmacal Research

, Volume 28, Issue 2, pp 243–248 | Cite as

Transdermal delivery of piroxicam using microemulsions

  • Eun-Seok Park
  • Yu Cui
  • Bum-Jin Yun
  • In-Ja Ko
  • Sang-Cheol Chi
Drug efficacy

Abstract

To improve the skin permeability of piroxicam, a new oil-in-water microemulsion containing 0.5% piroxicam was developed. Among various oils investigated for their suitability as an oil phase for the microemulsion system, oleic acid showed both excellent solubility and skin permeation enhancing effect for piroxicam. Microemulsion existence ranges were identified through the construction of the pseudo-ternary phase diagram. The effect of the content of oleic acid and the ratio of the surfactant/cosurfactant on skin permeation of piroxicam were evaluated with excised rat skins. The optimum formulation with the highest skin permeation rate (47.14 μg/cm2/h) consisted of 0.5% piroxicam, 10% oleic acid, 60% Labrasol/ethanol (1:5) and water.

Key words

Piroxicam Microemulsion Oleic acid Phase diagram Skin permeability 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Babar, A., Solanki, U. D., Cutie, A. J., and Plakogiannis, F., Piroxicam release from dermatological bases:In vitro studies using cellulose membrane and hairless mouse skin.Drug Dev. Ind. Pharm., 16, 523–540 (1990).CrossRefGoogle Scholar
  2. Baroli, B., Lopez-Quintela, M. A., Delgado-Charro, M. B., Fadda, A. M., and Blanco-Mendez, J., Microemulsions for topical delivery of 8-methoxsalen.J. Control Rel., 69, 209–218 (2000).CrossRefGoogle Scholar
  3. Buyuktimkin, N., Buyuktimkin, S., and Rytting, J. H., Chemical means of transdermal drug permeation enhancement. In: Ghosh, T.K., Pfister, W.R., Yum, S.I. (Eds.), Transdermal and Topical Drug Delivery Systems, Interpharm Press, IL, pp. 357–475 (1997).Google Scholar
  4. Curdy, C., Kalia, Y. N., Naik, A., and Guy, R. H., Piroxicam delivery into human stratum corneumin vivo: iontophoresis versus passive diffusion.J. Control Rel., 76, 73–79 (2001).CrossRefGoogle Scholar
  5. Delgado-Charro, M. B., Iglesias-Vilas, G., Blanco-Mendez, J., Lopez-Quintela, M. A., Marty, J.-P., and Guy, R. H., Delivery of a hydrophilic solute through the skin from novel microemulsion systems.Eur. J. Pharm. Biopharm., 43, 37–42 (1997).CrossRefGoogle Scholar
  6. Doliwa, A., Santoyo, S., and Ygartua, P., Effect of passive and iontophoretic skin pretreatments with terpenes on thein vitro skin transport of piroxicam.Int. J. Pharm., 229, 37–44 (2001).PubMedCrossRefGoogle Scholar
  7. Gay, C. L., Green, P. G., Guy, R. H., and Francoeur, M. L., Iontophoretic delivery of piroxicam across the skinin vitro. J. Control Rel., 22, 57–67 (1992).CrossRefGoogle Scholar
  8. Gao, S. and Singh, J., Effect of oleic acid/ethanol and oleic acid/ propylene glycol on thein vitro percutaneous absorption of 5-fluorouracil and tamoxifen and the macroscopic barrier property of porcine epidermis.Int. J. Pharm., 165, 45–55 (1998).CrossRefGoogle Scholar
  9. Hsu, L. R., Huang, Y. B., Wu, P. C., and Tsai, Y. H., Percutaneous absorption of piroxicam from FAPG base through rat skin: effects of oleic acid and saturated fatty acid added to FAPG base.Drug Dev. Ind. Pharm., 20, 1425–1437 (1994).CrossRefGoogle Scholar
  10. Huang, Y.-B., Wu, P.-C., Ko, H.-M., and Tsai, Y.-H., Cardamom oil as a skin permeation enhancer for indomethacin, piroxicam and diclofenac.Int. J. Pharm., 126, 111–117 (1995).CrossRefGoogle Scholar
  11. Kanikkannan, N., Kandimalla, K., Lamba, S. S., and Singh, M., Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery.Curr. Med. Chem., 7, 593–608 (2000).PubMedGoogle Scholar
  12. Kawakami, K., Yoshikawa, T., Moroto, Y., Kanaoka, E., Takahashi, K., Nishihara, Y., and Masuda, K., Microemulsion formulation for enhanced absorption of poorly soluble drugs: I. Prescription design.J. Control Rel., 81, 65–74 (2002).CrossRefGoogle Scholar
  13. Kreilgaard, M., Influence of microemulsions on cutaneous drug delivery.Adv. Drug Deliv. Rev., 54, S77-S98 (2002).PubMedCrossRefGoogle Scholar
  14. Okuyama, H., Ikeda, Y., Kasai, S., Imamori, K., Takayama, K., and Nagai, T., Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm.Int. J. Pharm., 186, 141–148 (1999).PubMedCrossRefGoogle Scholar
  15. Peltora, S., Saarinen-Savolanien, P., Kiesvaara, J., Suhonen, T.M. and Urtti, A., Microemulsion for topical delivery of estradiol.Int. J. Pharm., 254, 99–107 (2003).CrossRefGoogle Scholar
  16. Rhee, Y.-S., Choi, J.-G., Park, E.-S., and Chi, S.-C., Transdermal delivery of ketpoprofen using microemulsions.Int. J. Pharm., 228, 161–170 (2002).CrossRefGoogle Scholar
  17. Santoyo, S., Arellano, A., Ygartua, P., and Martin, C., Penetration enhancer effects on thein vitro percutaneous absorption of piroxicam through rat skin.Int. J. Pharm., 117, 219–224 (1995).CrossRefGoogle Scholar
  18. Santoyo, S. and Ygartua, P., Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application.Eur. J. Pharm. Biopharm., 50, 245–250 (2000).PubMedCrossRefGoogle Scholar
  19. Schiantarelli, P. and Cadel, S., Piroxicam pharmacology activity and gastrointestinal damage by oral and rectal route.Arzneim-Forsch., 31, 87–92 (1981).Google Scholar
  20. Schiantarelli, P., Cadel, S., Acerbi, D., and Pavesi, L., Anti-inflammatory activity and bioavailability of percutaneous piroxicam.Arzneim.-Forsch., 32, 230–235 (1982).Google Scholar
  21. Tessari, L., Ceciliani, L., Belluati, A., Letizia, G., Martorana, U., Pagliara, L., Pognani, A., Thovez, G., Siclari, A., and Torri, G., Aceclofenac cream versus piroxicam cream in the treatment of patients with minor traumas and phlogistic affections of soft tissues: a double-blind study.Curr. Ther. Res., 56, 702–712 (1995).CrossRefGoogle Scholar
  22. Thacharodi, D. and Rao, K. P., Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers.Int. J. Pharm., 111, 235–240 (1994).CrossRefGoogle Scholar
  23. Troconiz, J. I., Lopez-Bustamante, L. G., and Fos, D., High-performance liquid chromatographic analysis of piroxicam and tenoxicam in plasma, blood and buffer solution. Application to pharmacokinetic studies in small laboratory animals.Arzneim-Forsch., 43, 679–681 (1993).Google Scholar
  24. Tsai, Y.-H., Hsu, L.-R., and Naito, S.-I., Percutaneous absorption of piroxicam from ointment bases in rabbits.Int. J. Pharm., 24, 61–78 (1985).CrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2005

Authors and Affiliations

  • Eun-Seok Park
    • 1
  • Yu Cui
    • 1
  • Bum-Jin Yun
    • 1
  • In-Ja Ko
    • 1
  • Sang-Cheol Chi
    • 1
  1. 1.College of PharmacySungkyunkwan UniversitySuwon, Kyunggi-DoKorea

Personalised recommendations